Mary Cushman: Unprovoked VTE as a Marker of Increased Cardiovascular Mortality Risk
Mary Cushman, University Distinguished Professor and Vice Chair at the University of Vermont, shared Debora Kamin Mukaz‘s post on LinkedIn, adding:
“Alert! People with unprovoked VTE have double the risk of death than those without VTE.
Their leading cause of death is circulatory disease.
When you are seeing patients with VTE think big picture.
Start a statin if indicated.
Get bold pressure less than 130.
Talk about smoking cessation.”
Debora Kamin Mukaz, Assistant Professor of Medicine at Larner College of Medicine at the University of Vermont, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Thrombosis and Haemostasis:
“We published a new paper on long-term mortality and causes of death after venous thromboembolism (VTE) in Journal of Thrombosis and Haemostasis (JTH).
People with any VTE were approximately 3 times more likely to die over 5 years than those without VTE.
The 5-year mortality risk were approximately 6-fold for cancer-provoked VTE and 2-fold for unprovoked and other-provoked VTE.
Those with cancer-provoked VTE were most likely to die of cancer, but circulatory diseases were the main causes of death after all other types of VTE.
This suggests that enhanced cardiovascular prevention in patients with VTE might delay mortality.”
Title: Long-term mortality and causes of death after venous thromboembolism: findings from the Atherosclerosis Risk in Communities Cohort Study
Authors: Debora Kamin Mukaz, Aixin Li, Weihua Guan, Rui Cao, Lingfeng Huo, Weihong Tang, Pamela L Lutsey, Neil A Zakai, Aaron R Folsom, Mary Cushman
Other posts featuring Mary Cushman on Hemostasis Today.
-
Oct 20, 2026, 06:45Grant Garcia: Why Does a Blood Clot Diagnosis Immediately End an Athlete’s Season?
-
Oct 20, 2026, 06:35Parag Tamhankar: Landmark Study Reveals Genetic Spectrum and Targeted Therapies for ALPS in the Indian Population
-
Oct 20, 2026, 06:26Nina Houben: Neonatal Blood Transfusion Symposium and PhD Defense
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question